Amyotrophic Lateral Sclerosis (ALS)

Neuralstem Phase 1 Stem Cell Trial Shows Safety, Possible Efficacy

Neuralstem's spinal cord stem cells, and the surgical technique used to transplant them, proved to be safe and well-tolerated in a phase 1 clinical trial in 12 people with amyotrophic lateral sclerosis (ALS). Although the trial wasn't designed to show efficacy, one participant showed signs of clinical improvement.

ALS TDI Webinar: TDI 132 Project Overview

An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.

MDA 2012 Conference Report: Genetics and Immunology Update

More than 500 physicians, allied health care professionals and MDA staff attended the MDA's 2012 Clinical Conference in Las Vegas, March 4-7.

The program emphasized:

MDA and ALS TDI Extend Partnership Through 2012

MDA has extended its strategic research partnership with the ALS Therapy Development Institute (ALS TDI) through 2012 and awarded a $2 million grant to support the nonprofit biotech's continued efforts to develop treatments forALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Rhinoceros, Kenya, 2001

Angelo became a nature and wildlife photographer and writer in 1997.  A year later he received a diagnosis of ALS (Lou Gehrig’s disease), but has continued to travel and publish marvelous works.  His magazine photo credits include Nature Photographer, Natural History and MDA’s Quest.

MDA Genetic Counseling Webinar Answers Key Questions

Respondents to MDA’s Transitions Survey — in other words, people with a neuromuscular disease who are in their teens through late 30s — made it clear they had questions about the genetics of their disease, as well as questions about family planning and the value of diagnostic testing.

MDA’s Genetic Counseling Webinar, which occurred Feb. 22, 2012, answers many of those questions.

ALS Research Briefs: MSP, Metabolic Proteins

Below are highlights of two recent studies in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

ALS TDI to Test Multiple Sclerosis Drug in ALS

A phase 2 clinical trial is set to begin of TDI 132, a compound that modulates the immune system, the ALS Therapy Development Institute (ALS TDI) announced today.

TDI 132, also known as fingolimod (brand name Gilenya), already is approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple sclerosis.

SMA Gene Associated with Sporadic ALS

Duplications (extra copies) of the SMN1 gene are a "major" risk factor for developing sporadic (noninherited) ALS (amyotrophic lateral sclerosis), a team of scientists based in the Netherlands and United Kingdom has reported.

MDA Commits $12 Million to Neuromuscular Disease Research

The Muscular Dystrophy Association has awarded 38 new grants totaling more than $12 million to fund research projects focused on its continuing mission to uncover the causes of, and develop therapies for, the more than 40 neuromuscular diseases in its program.

MDA's Board of Directors reviewed and approved the new grants based on recommendations from the Association's Scientific and Medical Advisory Committees, and the grants took effect Feb. 1.

Pages